Phase I/II study of the oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML).

被引：0
|
作者：
Garcia-Manero, Guillermo
Yang, Allen S.
Giles, Francis
Faderl, Stefan
Ravandi, Farhad
Cortes, Jorge
Newsome, Willie M.
Issa, Jean-Pierre
Patterson, Tracy-Ann
Dubay, Marja
Li, Zuomei
Kantarjian, Hagop
Martell, Robert E.
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ So Calif, Norris Comprehens Canc Ctr, Div Hematol, Los Angeles, CA USA
[3] MethylGene Inc, Montreal, PQ, Canada
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1954
引用
收藏
页码：552A / 553A
页数：2
相关论文
共 50 条
  • [31] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [32] Phase I/II Study of Vosaroxin and Decitabine in Newly Diagnosed Older Patients (pts) with Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
    Naval, Daver
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Pemmaraju, Naveen
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Jain, Nitin
    Borthakur, Gautam
    Jabbour, Elias
    Konopleva, Marina
    Cortes, Jorge E.
    Craig, Adam
    Ravandi, Farhad
    BLOOD, 2014, 124 (21)
  • [33] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Kadia, Tapan M.
    Jabbour, Elias
    Pemmaraju, Naveen
    Faderl, Stefan
    Borthakur, Gautam
    Thomas, Deborah A.
    Daver, Naval Guastad
    Ravandi, Farhad
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] A Phase II Study of Twice Daily Cytarabine and Fludarabine and Gentuzumab Ozogamycin (GO) In Patients (pts) with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Ghanem, Hady Antoine
    Ravandi, Farhad
    Faderl, Stefan
    Cortes, Jorge
    Reyes, Ardes S.
    O'Brien, Susan
    Borthakur, Gautam
    Kadia, Tapan
    Burger, Jan A.
    Konopleva, Marina
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 903 - 903
  • [35] A Final Report: Phase I/II Study of Sequential Azacitidine and Lenalidomide in Patients with Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Daver, Naval
    Jabbour, Elias
    Kadia, Tapan
    Borthakur, Gautam
    Konopleva, Marina
    Pemmaraju, Naveen
    Yang, Hui
    Wei, Yue
    Wierda, William G.
    Bueso-Ramos, Carlos E.
    Patel, Keyur P.
    Cortes, Jorge E.
    Ravandi, Farhad
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
  • [36] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Borthakur, Gautam
    Huang, Xuelin
    Kantarjian, Hagop
    Faderl, Stefan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Torma, Ritva
    Morris, Gail
    Berry, Donald
    Issa, Jean-Pierre
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 73 - 78
  • [37] An Assessment of the RIFLE Criteria for Acute Kidney Injury (AKI) and Mortality in Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS).
    Mattiuzzi, Gloria
    Lahoti, Amit
    Salahudeen, Abdulla
    Ravandi, Farhad
    Cortes, Jorge
    Vu, Khanh
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 419 - 420
  • [38] Antifungal Prophylaxis (AFP) for Patients (Pts) with Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS) Undergoing Intensive Chemotherapy: An Experience with 730 Pts
    Mattiuzzi, Gloria
    Kantarjian, Hagop
    Ho, Jennifer
    Garcia-Manero, Guillermo
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1206 - 1206
  • [39] Causes of death in patients (pts) with acute myelogenous lukemia (AML) and high-risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy (IC).
    Mattiuzzi, GN
    Alvarado, G
    Alvarez, R
    Pierce, S
    Cortes, J
    Kantarjian, H
    Giles, F
    Faderl, S
    Estey, E
    BLOOD, 2003, 102 (11) : 878A - 878A
  • [40] A Phase II Study of Azacitidine and Sirolimus for the Treatment of Acute Myeloid Leukemia (AML) Refractory to or Not Eligible for Intensive Chemotherapy or High Risk Myelodysplastic Syndrome (MDS)
    Palmisiano, Neil
    Jeschke, Grace
    Wilde, Lindsay
    Leiby, Benjamin E.
    Alpdogan, Onder
    Carabasi, Matthew
    Filicko-O'Hara, Joanne
    Gaballa, Sameh
    Grosso, Dolores
    Klumpp, Thomas R.
    Outschoorn, Ubaldo Martinez
    Wagner, John L.
    Carroll, Martin
    Porcu, Pierluigi
    Flomenberg, Neal
    Perl, Alexander E.
    Kasner, Margaret
    BLOOD, 2017, 130
12345